EMTT and shockwave therapy (ESWT) are often lumped together, but they work through different mechanisms. Whether you need one, the other, or both depends less on which body part hurts than on what is wrong with the tissue underneath.
Two tools, two jobs
ESWT (extracorporeal shockwave therapy) is mechanical. A handpiece delivers focused or radial pressure waves into tissue. That mechanical stimulus is thought to change fibroblast behavior and influence how disorganized scar tissue remodels. It does not physically tear adhesions apart.
EMTT (extracorporeal magnetotransduction therapy) is not a shockwave. It is a high-intensity magnetic field delivered through a loop applicator. It reaches a whole volume of tissue, bone included, with no mechanical impact. Its proposed effects are at the cellular level, on the metabolism of the cells doing the healing.
That difference in mechanism is why the answer to "which treatment do I need" changes with the injury.
Can EMTT alone help an early bone stress injury?
Direct clinical evidence is thin. A 2026 scoping review of EMTT for bone healing found nine studies in total: two laboratory studies, six case reports and one pilot clinical trial, with no randomized trials. Most of the clinical reports combined EMTT with shockwave, so the effect of EMTT on its own is hard to separate. None of those studies was a trial of EMTT for stress fractures, and a suspected stress fracture first needs its own diagnosis, usually with imaging.
A stress fracture, or its earlier stage (a bone stress reaction or bone marrow edema), is mainly a bone-remodeling problem rather than a movement problem. There is usually no scar tissue blocking glide and no adhesion tethering one structure to another. Microdamage from repetitive load has outpaced bone remodeling, and the bone's repair cells, the osteoblasts, have to catch up.
The rationale for EMTT in that setting comes from laboratory work. A 2024 study in Biomedicines exposed cultured human osteoblasts to EMTT. The authors report that key bone-formation genes, including SP7, RUNX2, COL1A1, ALPL and BGLAP, were expressed more than sevenfold above untreated cells, with more collagen and mineral deposited and no loss of cell viability. A 2022 study in Electromagnetic Biology and Medicine treated human bone-marrow stem cells with EMTT for 10 minutes three times a week and found higher levels of VEGF, a signal involved in forming new blood vessels, after seven days at 80 mT, again without toxic effects. These are cell studies. They support a plausible mechanism, not a proven patient outcome.
The scoping review's authors describe EMTT as a safe and potentially useful non-operative option, mainly as an adjunct to shockwave, and call for randomized trials. That is a fair summary of where the field stands: promising for bone, early in the evidence, and not a stand-alone stress-fracture treatment whose results we can promise.
Why a joint or tendon injury often needs both
Chronic tendinopathy and joint pain are a different story. As we have covered before, adhesion can be one of the things that keeps this kind of pain going. An old injury can heal into dense, poorly organized scar-like tissue. That tissue restricts glide between tendon, muscle, and fascia and changes how load moves through the joint. The mechanical problem sits on top of a cellular one. Treating only the cellular side leaves the mechanical restriction in place.
The best evidence for combining the two comes from a 2018 randomized controlled trial of 86 patients with rotator cuff tendinopathy. Every patient received three shockwave sessions plus eight sessions of either active EMTT or sham EMTT. Both groups improved. At 24 weeks, the active-EMTT group had significantly greater pain reduction, and its Constant-Murley shoulder function scores also improved significantly more than with shockwave plus sham EMTT. The trial shows an added benefit in that population. It does not show that every shoulder needs both treatments. The wider shockwave evidence for rotator cuff tendinopathy is reviewed separately.
A larger 2026 double-blind, placebo-controlled trial tested EMTT on its own. It randomized 126 patients with knee osteoarthritis (31), rotator cuff enthesopathy (43), or lumbar spondyloarthrosis (52) to eight weekly EMTT sessions or sham. Across the whole trial, pain scores at 12 weeks were 2.2 with EMTT and 4.2 with placebo. So EMTT showed benefit on its own in that mixed group of degenerative joint and enthesis pain. The tendon trial adds that, in rotator cuff tendinopathy, combining the two produced more improvement than shockwave with sham EMTT. Our reading is that this matters most when adhesion or altered mechanics are part of the problem.
When a bone injury stalls, the same logic applies
Once a bone injury stops behaving like a fresh, remodeling stress reaction and becomes a delayed union or nonunion, healing has stalled. Combining EMTT with ESWT then becomes useful again, for the same reason it helps a stuck tendon.
A 2025 case-control pilot study in the Journal of Orthopaedic Surgery and Research followed patients recovering from foot and ankle surgery (talar osteochondral defects, fractures, and joint disease). Patients who received combined ESWT and EMTT were compared with matched controls. At four weeks, radiographic healing was visible in 8 of 10 treated patients and 2 of 10 controls. Weight-bearing pain was lower (0.2 versus 3.1 on a 0–10 scale), and the treated group returned to activity roughly nine weeks sooner on average. A 2024 case report (level IV evidence) described a 14-year-old athlete whose calcaneal fracture next to the growth plate had not united after eight weeks. Five weekly sessions combining two types of focused shockwave with EMTT, with full weight-bearing allowed, were followed by near-complete healing on CT at six weeks, without early closure of the growth plate. A single case cannot separate the effect of each treatment.
The thread is consistent. Fresh, remodeling bone may need only a cellular signal. Bone or soft tissue that has become mechanically stuck, by scar tissue, adhesion, or stalled healing, tends to do better when a mechanical tool is added.
What this means for you
There is no universal answer to "EMTT, or EMTT plus shockwave?" It depends on whether the injury is mainly a cell-biology issue, such as a fresh stress reaction, or has a mechanical problem layered on top, such as adhesion, restricted glide, or stalled healing. We examine first, and the tools we use follow the diagnosis. How EMTT works explains how we use it at our Denver Tech Center clinic.
If a bone stress injury is not settling with rest, or a joint or tendon problem has outlasted normal recovery, book a new patient exam. We will work out which side of this line your injury falls on.
Sources
- Charles R, Vlasak A, Turner T, et al. Extracorporeal magnetotransduction therapy as an adjunctive and primary modality for bone healing: a scoping review of current evidence. Electromagnetic Biology and Medicine. 2026;45(3):313-320. PMID 41885227. (link)
- Gerdesmeyer L, Tübel J, Obermeier A, et al. Extracorporeal magnetotransduction therapy as a new form of electromagnetic wave therapy: from gene upregulation to accelerated matrix mineralization in bone healing. Biomedicines. 2024;12(10):2269. PMID 39457582. (link)
- Gerdesmeyer L, Zielhardt P, Klüter T, et al. Stimulation of human bone marrow mesenchymal stem cells by electromagnetic transduction therapy (EMTT). Electromagnetic Biology and Medicine. 2022;41(3):304-314. PMID 35670281. (link)
- 2025 case-control pilot study in the Journal of Orthopaedic Surgery and Research on foot and ankle surgery recovery. (link)
- Knobloch K, Saxena A, Schaden W. Combined electromagnetic and electrohydraulic focused ESWT and EMTT for delayed calcaneal union in an adolescent parkour athlete: a case report. Open Access Journal of Sports Medicine. 2024;15:61-66. PMID 38883555. (link)
- Randomized controlled trial of 86 patients with rotator cuff tendinopathy comparing shockwave plus sham EMTT to shockwave plus active EMTT. (link)
- 2026 double-blind, placebo-controlled trial of 126 patients with knee osteoarthritis, rotator cuff enthesopathy, or lumbar spondyloarthrosis randomized to EMTT or sham. (link)
